| scholarly article | Q13442814 |
| P50 | author | Linqi Zhang | Q91516083 |
| Tongqing Zhou | Q47503126 | ||
| Xiaoxu Han | Q87777269 | ||
| P2093 | author name string | Han Wang | |
| Hua Wang | |||
| Hong Shang | |||
| Shasha Shi | |||
| Yangyang Li | |||
| Xuanling Shi | |||
| Panpan Zhou | |||
| Zihao Li | |||
| Jiapeng Wu | |||
| Mengqi Fang | |||
| P2860 | cites work | HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor | Q22242268 |
| Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors | Q27643993 | ||
| Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01 | Q27663293 | ||
| Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding | Q27670829 | ||
| Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing | Q27671696 | ||
| Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies | Q27674878 | ||
| Identification of Near-Pan-neutralizing Antibodies against HIV-1 by Deconvolution of Plasma Humoral Responses | Q88582157 | ||
| Structural Definition of a Unique Neutralization Epitope on the Receptor-Binding Domain of MERS-CoV Spike Glycoprotein | Q89568621 | ||
| Multidonor Analysis Reveals Structural Elements, Genetic Determinants, and Maturation Pathway for HIV-1 Neutralization by VRC01-Class Antibodies | Q27679353 | ||
| Crystal Structure of a Soluble Cleaved HIV-1 Envelope Trimer | Q27680496 | ||
| Cryo-EM Structure of a Fully Glycosylated Soluble Cleaved HIV-1 Envelope Trimer | Q27680497 | ||
| WebLogo: A Sequence Logo Generator | Q27860646 | ||
| CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1 | Q28646859 | ||
| Antibody neutralization and escape by HIV-1 | Q29547345 | ||
| Mechanisms of viral membrane fusion and its inhibition | Q29616090 | ||
| The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain | Q29618472 | ||
| Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies | Q29619015 | ||
| Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection | Q29619510 | ||
| Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1 | Q29619511 | ||
| HIV/AIDS epidemiology, pathogenesis, prevention, and treatment | Q30356074 | ||
| Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies | Q33614365 | ||
| Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies | Q33719511 | ||
| Early antibody therapy can induce long-lasting immunity to SHIV | Q33762877 | ||
| Loss of Asparagine-Linked Glycosylation Sites in Variable Region 5 of Human Immunodeficiency Virus Type 1 Envelope Is Associated with Resistance to CD4 Antibody Ibalizumab | Q33810849 | ||
| Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity | Q34204325 | ||
| Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies | Q34392963 | ||
| CD4-induced activation in a soluble HIV-1 Env trimer | Q34510675 | ||
| HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1. | Q34527469 | ||
| Engineered Bispecific Antibodies with Exquisite HIV-1-Neutralizing Activity | Q34531219 | ||
| HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption | Q34531858 | ||
| The survival benefits of AIDS treatment in the United States | Q34533291 | ||
| Genetic and Neutralization Sensitivity of Diverse HIV-1 env Clones from Chronically Infected Patients in China | Q34800408 | ||
| Conformational dynamics of single HIV-1 envelope trimers on the surface of native virions | Q35006601 | ||
| Structure and immune recognition of trimeric pre-fusion HIV-1 Env. | Q35142291 | ||
| Mechanism of Neutralization by the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 | Q35192782 | ||
| Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors | Q35382871 | ||
| HIV-1 fitness cost associated with escape from the VRC01 class of CD4 binding site neutralizing antibodies | Q35640998 | ||
| HIV-1 dynamics in vivo: implications for therapy | Q35701633 | ||
| Enhanced HIV-1 neutralization by antibody heteroligation | Q35735385 | ||
| CATNAP: a tool to compile, analyze and tally neutralizing antibody panels | Q35810109 | ||
| Selection Pressure on HIV-1 Envelope by Broadly Neutralizing Antibodies to the Conserved CD4-Binding Site | Q35943521 | ||
| Delineating CD4 dependency of HIV-1: Adaptation to infect low level CD4 expressing target cells widens cellular tropism but severely impacts on envelope functionality. | Q36298503 | ||
| Broadly Neutralizing Antibodies Developed by an HIV-Positive Elite Neutralizer Exact a Replication Fitness Cost on the Contemporaneous Virus | Q36397394 | ||
| A Single Residue within the V5 Region of HIV-1 Envelope Facilitates Viral Escape from the Broadly Neutralizing Monoclonal Antibody VRC01 | Q36466846 | ||
| Towards HIV-1 remission: potential roles for broadly neutralizing antibodies | Q36515149 | ||
| Selection for specific sequences in the external envelope protein of human immunodeficiency virus type 1 upon primary infection | Q36647820 | ||
| Bispecific Anti-HIV-1 Antibodies with Enhanced Breadth and Potency | Q37145901 | ||
| HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice | Q37236504 | ||
| HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. | Q37259407 | ||
| Common principles and intermediates of viral protein-mediated fusion: the HIV-1 paradigm | Q37348882 | ||
| Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption | Q37624842 | ||
| Of Mice, Macaques, and Men: Broadly Neutralizing Antibody Immunotherapy for HIV-1. | Q38643834 | ||
| Determinants of HIV-1 CD4-independent brain adaptation. | Q38719228 | ||
| Persistence of VRC01-resistant HIV-1 during antiretroviral therapy | Q39036775 | ||
| Antibody-virus co-evolution in HIV infection: paths for HIV vaccine development | Q39108751 | ||
| Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection | Q40173380 | ||
| Virological Control by the CD4-Binding Site Antibody N6 in Simian-Human Immunodeficiency Virus-Infected Rhesus Monkeys | Q40187584 | ||
| Quantification of the Impact of the HIV-1-Glycan Shield on Antibody Elicitation | Q40226810 | ||
| Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth. | Q40449526 | ||
| Corrigendum: Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. | Q40743748 | ||
| HIV: Potency needs constancy | Q41690058 | ||
| Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail. | Q41933482 | ||
| Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques | Q41933491 | ||
| Anti-CD4 Monoclonal Antibody Ibalizumab Exhibits Breadth and Potency Against HIV-1, With Natural Resistance Mediated by the Loss of a V5 Glycan in Envelope | Q45901244 | ||
| Fc receptor but not complement binding is important in antibody protection against HIV. | Q46545827 | ||
| Tandem bispecific neutralizing antibody eliminates HIV-1 infection in humanized mice. | Q52692811 | ||
| Rational design of a trispecific antibody targeting the HIV-1 Env with elevated anti-viral activity | Q53081267 | ||
| HIV-1 Vaccines Based on Antibody Identification, B Cell Ontogeny, and Epitope Structure | Q54210145 | ||
| Diverse pathways of escape from all well-characterized VRC01-class broadly neutralizing HIV-1 antibodies | Q57003103 | ||
| Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys | Q57039969 | ||
| Recent progress in broadly neutralizing antibodies to HIV | Q58569712 | ||
| Tracing HIV-1 strains that imprint broadly neutralizing antibody responses | Q59054303 | ||
| Combination therapy with anti-HIV-1 antibodies maintains viral suppression | Q59090059 | ||
| Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals | Q59351843 | ||
| CD4 occupancy triggers sequential pre-fusion conformational states of the HIV-1 envelope trimer with relevance for broadly neutralizing antibody activity | Q61815651 | ||
| P275 | copyright license | Creative Commons CC0 License | Q6938433 |
| P6216 | copyright status | copyrighted, dedicated to the public domain by copyright holder | Q88088423 |
| P433 | issue | 6 | |
| P304 | page(s) | e1007819 | |
| P577 | publication date | 2019-06-13 | |
| P1433 | published in | PLOS Pathogens | Q283209 |
| P1476 | title | Broadly resistant HIV-1 against CD4-binding site neutralizing antibodies | |
| P478 | volume | 15 |
Search more.